Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs PACCAR Inc. Common Stock (PCAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs PACCAR Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while PACCAR Inc. Common Stock trades at $109.43 (market cap $57.14B). The key difference: PACCAR Inc. Common Stock is far larger — about 58.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and PACCAR Inc. Common Stock pays a 1.29% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and PACCAR Inc. Common Stock for 6 Days on average.
| MRVI | PCAR | |
|---|---|---|
Market Cap | $977.37M | $57.14B |
Volume | 2,742,564 | 2,748,310 |
Sector | Health | Industrials |
52-Week High | $9.00 | $138.21 |
52-Week Low | $2.83 | $94.15 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $63.00B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PACCAR (PCAR) trades at $107.98, down 0.14% with bearish technical signals but strong fundamentals including 9% net income margin and 12.76% ROE. Recent earnings beat expectations in Q2 2026 with $1.43 EPS versus $1.36 expected. The company maintains stable cash flows with $4.3B operating cash flow projected for 2026 and recently declared a $0.35 quarterly dividend payable December 2026.
PCAR presents a mixed outlook with Wall Street consensus price target of $134.83 suggesting 25% upside potential, though technical indicators show bearish momentum. Key risks include sector sensitivity to interest rates and industrial cyclicality, while opportunities lie in the company's strong profitability metrics and defensive non-trucking segments representing over 60% of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About PACCAR Inc. Common Stock
PACCAR designs and manufactures heavy-duty trucks under brands including Peterbilt, Kenworth, and DAF. It also provides parts, financial services, and technology for commercial vehicles.
Read more on PCAR →
